A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has found that a combination prostate cancer treatment could prevent the disease from progressing into a harder-to-treat form of cancer in select patients.

The study, TALAPRO-3 (NCT04821622), evaluated a combination of two drugs—talazoparib and enzalutamide—in patients with metastatic castration-sensitive prostate cancer. This is a form of the disease that has spread beyond the prostate but remains susceptible to standard hormone therapy treatment.

The patients involved also had prostate cancer affected by certain gene mutations, including but not limited to BRCA1 and BRCA2 mutations, that often signal more aggressive disease.